AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1335008 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive daytime ambulatory blood pressure
Number of subjects: 28
Study 1335008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-measured random-zero sphygmomanometer resting blood pressure
Number of subjects: 28
Study 1335008 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise systolic blood pressure
Number of subjects: 28
Study 1335008 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic left ventricular mass
Number of subjects: 28
Study 4003917 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aerosol, 4 inhalations twice a day (b.i.d.), total dose 336 micrograms/day for 8 weeks
Number of subjects: 89
Study 4003917 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol, 4 inhalations twice a day (b.i.d.) for 8 weeks
Number of subjects: 89
Study 4003917 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aerosol, 2 inhalations 4 times a day (q.i.d.), total dose 336 micrograms/day for 2 weeks
Number of subjects: 89
Study 4003917 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aerosol, both b.i.d. and q.i.d. regimens
Number of subjects: 89
Study 31562508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 5046
Study 31562508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash + LNS
Number of subjects: 5046
Study 31562508 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS
Number of subjects: 5046
Study 31562508 — intervention group
Group type: COMPARATOR
Intervention: SNACK (control)
Number of subjects: 5046
Study 28436145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 33
Study 28436145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg
Number of subjects: 33
Study 28436145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25823620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (specifics not provided)
Number of subjects: 0
Study 25823620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 25823620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (nutrition intervention)
Number of subjects: 0
Study 25823620 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 0
Study 25823620 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 0
Study 24657333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide users
Number of subjects: 328
Study 24657333 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrochlorothiazide participants
Number of subjects: 328
Study 22456947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bernese periacetabular osteotomy (PAO)
Number of subjects: 26
Study 20373168 — intervention group
Group type: EXPERIMENTAL
Intervention: Family medicine clerkship with a 3-hour workshop on clinical reasoning using illness scripts.
Number of subjects: 53
Study 20373168 — intervention group
Group type: COMPARATOR
Intervention: Psychiatry clerkship (control).
Number of subjects: 53
Study 18632187 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal compression
Number of subjects: 50
Study 18632187 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 50
Study 18632187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg's position with abdominal compression
Number of subjects: 50
Study 18632187 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver in reverse Trendelenburg's position
Number of subjects: 50
Study 19450096 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1327
Study 19450096 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1327
Study 15034161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 100 mg/day in addition to tacrolimus
Number of subjects: 70
Study 15034161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketoconazole)
Number of subjects: 70
Study 11282779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Inspiration (DI)
Number of subjects: 19
Study 9389427 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured NIDDM care with diabetes service support (SG)
Number of subjects: 350
Study 9389427 — intervention group
Group type: COMPARATOR
Intervention: Standard care without diabetes service support (CG)
Number of subjects: 350
Study 7614594 — intervention group
Group type: EXPERIMENTAL
Intervention: dietetic therapy of chinese herb rhizome wheat starch
Number of subjects: 30
Study 7614594 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 30
Study 3277325 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiation therapy with additional cyclophosphamide (Cytoxan) or estramustine phosphate (Emcyt) chemotherapy for 2 years
Number of subjects: 254
Study 3277325 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiation therapy only
Number of subjects: 254
Study 31269203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 48
Study 31269203 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 48
Study 31269203 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 48
Study 28008609 — intervention group
Group type: EXPERIMENTAL
Intervention: FITT-C (n = 133)
Number of subjects: 250
Study 28008609 — intervention group
Group type: COMPARATOR
Intervention: TS (n = 117)
Number of subjects: 250
Study 27671243 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive treadmill walking exercise training for 12 weeks
Number of subjects: 10
Study 25257905 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone cement (ABC)
Number of subjects: 53
Study 25257905 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone dust (ABD)
Number of subjects: 53
Study 25257905 — intervention group
Group type: COMPARATOR
Intervention: Blank control (BC)
Number of subjects: 53
Study 25257905 — intervention group
Group type: COMPARATOR
Intervention: Operation control (OC)
Number of subjects: 53
Study 25257905 — intervention group
Group type: COMPARATOR
Intervention: Ototoxicity positive control (OPC)
Number of subjects: 53
Study 22899947 — intervention group
Group type: EXPERIMENTAL
Intervention: Transamidated gluten (3.7 g/day)
Number of subjects: 47
Study 22899947 — intervention group
Group type: COMPARATOR
Intervention: Nontransamidated gluten (control group)
Number of subjects: 47
Study 19865058 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron
Number of subjects: 40
Study 19865058 — intervention group
Group type: COMPARATOR
Intervention: Parenteral iron only
Number of subjects: 40
Study 17711378 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus optimized background (ENF plus OB)
Number of subjects: 997
Study 17711378 — intervention group
Group type: COMPARATOR
Intervention: Optimized background (OB) only
Number of subjects: 997
Study 15746730 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest
Number of subjects: 200
Study 15746730 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvest
Number of subjects: 200
Study 12195238 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 plus MLT
Number of subjects: 14
Study 12195238 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 plus MLT plus NTX
Number of subjects: 14
Study 9529266 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens therapy at 0.625 mg daily
Number of subjects: 366
Study 7872882 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 107
Study 7872882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 2388978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose tablets
Number of subjects: 20
Study 2388978 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol tablets (control)
Number of subjects: 20
Study 832943 — intervention group
Group type: EXPERIMENTAL
Intervention: Undecylenic acid powder preparations
Number of subjects: 104
Study 832943 — intervention group
Group type: COMPARATOR
Intervention: Talc vehicle or left untreated
Number of subjects: 104
Study 31820289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (IBUD) 50 mg twice daily for 12 weeks
Number of subjects: 125
Study 31820289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 31820289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (IBUD)
Number of subjects: 125
Study 31120501 — intervention group
Group type: EXPERIMENTAL
Intervention: GA plus HCQ
Number of subjects: 112
Study 31120501 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 112
Study 28658112 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg propofol (LPE group)
Number of subjects: 363
Study 28658112 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg propofol (MPE group)
Number of subjects: 363
Study 28658112 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg propofol (HPE group)
Number of subjects: 363
Study 28658112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 2 mg/kg propofol (P group)
Number of subjects: 363
Study 28658112 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg propofol (E group)
Number of subjects: 363
Study 28658112 — intervention group
Group type: EXPERIMENTAL
Intervention: P group
Number of subjects: 363
Study 28658112 — intervention group
Group type: EXPERIMENTAL
Intervention: HPE group and P group
Number of subjects: 363
Study 25761129 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFSH 300 IU for 5 months
Number of subjects: 354
Study 25761129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 25761129 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFSH (200 IU and above)
Number of subjects: 354
Study 25761129 — intervention group
Group type: EXPERIMENTAL
Intervention: rhFSH
Number of subjects: 354
Study 23958526 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique
Number of subjects: 40
Study 23958526 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 40
Study 21368386 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2 mg/d
Number of subjects: 31
Study 21368386 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/d
Number of subjects: 31
Study 21368386 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 10 mg/d
Number of subjects: 31
Study 21368386 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg/d
Number of subjects: 31
Study 19267739 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy at a community hospital
Number of subjects: 42
Study 19267739 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy at a cancer centre
Number of subjects: 42
Study 16900105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 35
Study 16900105 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 16900105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD) with long allele homozygotes
Number of subjects: 35
Study 16900105 — intervention group
Group type: EXPERIMENTAL
Intervention: Long allele homozygotes
Number of subjects: 35
Study 16900105 — intervention group
Group type: EXPERIMENTAL
Intervention: Short allele carriers
Number of subjects: 35
Study 15482444 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct instructions for retrieval of original responses
Number of subjects: 0
Study 15482444 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect instructions allowing automatic responses
Number of subjects: 0
Study 15482444 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 11339776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane continued
Number of subjects: 120
Study 11339776 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane stopped
Number of subjects: 120
Study 11339776 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane continued
Number of subjects: 120
Study 11339776 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane stopped
Number of subjects: 120
Study 11339776 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol continued
Number of subjects: 120
Study 11339776 — intervention group
Group type: COMPARATOR
Intervention: Propofol stopped
Number of subjects: 120
Study 9692452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage combined with intrathecal papaverine (CSFDr + IP)
Number of subjects: 33
Study 9692452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CSFDr + IP)
Number of subjects: 33
Study 8156465 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with acetylsalicylic acid
Number of subjects: 436
Study 8156465 — intervention group
Group type: COMPARATOR
Intervention: Medical management (nonoperative)
Number of subjects: 436
Study 3345643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1-g tablet, four times a day for two days before and after theophylline dose)
Number of subjects: 8
Study 3345643 — intervention group
Group type: COMPARATOR
Intervention: Non-sustained-release theophylline (5-mg/kg dose)
Number of subjects: 8
Study 31688528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track catheter removal (day of surgery, 4 hours after surgery)
Number of subjects: 164
Study 31688528 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter removal (postoperative day 1)
Number of subjects: 164
Study 31227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of protein abundance and phosphopeptide abundance
Number of subjects: 150
Study 31227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual kinases
Number of subjects: 150
Study 31227600 — intervention group
Group type: EXPERIMENTAL
Intervention: Motif-based analysis
Number of subjects: 150
Study 27912982 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 μg (200 μg for those aged <11 years)
Number of subjects: 7138
Study 27912982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7138
Study 25966723 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus azithromycin (AZT group)
Number of subjects: 45
Study 25966723 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus metronidazole and amoxicillin (M+A group)
Number of subjects: 45
Study 25966723 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP) only
Number of subjects: 45
Study 23149171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency defined as 25(OH)D level <20 ng/mL
Number of subjects: 70
Study 23149171 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D levels measured at baseline, cessation of cardiopulmonary bypass, and 24 hours postoperatively
Number of subjects: 70
Study 23149171 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative 25(OH)D levels
Number of subjects: 70
Study 21785293 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing distance sprint interval training
Number of subjects: 12
Study 21785293 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing distance sprint interval training
Number of subjects: 12
Study 21785293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of sprint interval training
Number of subjects: 12
Study 19337684 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with financial funding
Number of subjects: 159
Study 19337684 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with sample size >78 patients
Number of subjects: 159
Study 19337684 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RCTs
Number of subjects: 159
Study 16936184 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 352
Study 16936184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 15201620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy with LDL-c level < 100 mg/dl
Number of subjects: 99
Study 15201620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy with LDL-c level > 100 mg/dl
Number of subjects: 99
Study 11726481 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous endurance exercise training programme (CT)
Number of subjects: 12
Study 11726481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent endurance exercise training programme (IT)
Number of subjects: 12
Study 9515854 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-use hygroscopic condenser humidifier
Number of subjects: 310
Study 9515854 — intervention group
Group type: COMPARATOR
Intervention: Heated-water humidification
Number of subjects: 310
Study 8042971 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (comprehensive relapse prevention program)
Number of subjects: 155
Study 8042971 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 155
Study 3076905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (median dose 125 mg)
Number of subjects: 0
Study 3076905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30807589 — intervention group
Group type: EXPERIMENTAL
Intervention: mF75 (isocaloric modified F75 without lactose and with reduced carbohydrate)
Number of subjects: 843
Study 30807589 — intervention group
Group type: COMPARATOR
Intervention: F75 (standard formula)
Number of subjects: 843
Study 30807589 — intervention group
Group type: EXPERIMENTAL
Intervention: mF75
Number of subjects: 843
Study 30807589 — intervention group
Group type: COMPARATOR
Intervention: F75
Number of subjects: 843
Study 28715944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low abrasive air polishing powder (Air‐Flow® Perio, EMS) (AFP)
Number of subjects: 20
Study 28715944 — intervention group
Group type: COMPARATOR
Intervention: Titanium curettes (TC)
Number of subjects: 20
Study 28715944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 26009206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociation from a beloved candy brand
Number of subjects: 0
Study 26009206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociation from beloved brands (implicit and explicit methods)
Number of subjects: 0
Study 26009206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociation from beloved brands
Number of subjects: 0
Study 23013513 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 72
Study 23013513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 72
Study 23013513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and ezetimibe
Number of subjects: 72
Study 21732834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (10 to 20 mg per kilogram of body weight per day)
Number of subjects: 1352
Study 21732834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1352
Study 21732834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 1352
Study 19380337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediwrap blanket
Number of subjects: 30
Study 19380337 — intervention group
Group type: COMPARATOR
Intervention: Forced air warming (FAW) blanket
Number of subjects: 30
Study 16402128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0
Study 16402128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 0
Study 16402128 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline smoking behaviour
Number of subjects: 0
Study 16402128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxycotinine/cotinine ratio
Number of subjects: 0
Study 15296689 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder and follow-up visit by a promotora
Number of subjects: 0
Study 15296689 — intervention group
Group type: COMPARATOR
Intervention: Postcard reminder only
Number of subjects: 0
Study 12483417 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional two‐compartment model
Number of subjects: 75
Study 12483417 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐compartment model accounting for RV spillover
Number of subjects: 75
Study 11075741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 1030
Study 11075741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg
Number of subjects: 1030
Study 11075741 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin and pravastatin
Number of subjects: 1030
Study 8610903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.7% at 1 MAC)
Number of subjects: 20
Study 8610903 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.2% at 1 MAC)
Number of subjects: 20
Study 1578625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair Hugger (BH)
Number of subjects: 16
Study 1578625 — intervention group
Group type: COMPARATOR
Intervention: Warming Blanket (WB)
Number of subjects: 16
Study 3932685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 83
Study 3932685 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 83
Study 3932685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa (crossover)
Number of subjects: 83
Study 3932685 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (crossover)
Number of subjects: 83
Study 3453428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg haloperidol/day for 14 days
Number of subjects: 48
Study 3453428 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg haloperidol/day for 14 days
Number of subjects: 48
Study 3453428 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adapted haloperidol dose for 14 days
Number of subjects: 48
Study 3453428 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment (10 mg or 20 mg haloperidol)
Number of subjects: 48
Study 31605794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (100 to 200 mg every 3 weeks for up to 16 cycles)
Number of subjects: 38
Study 31605794 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT)
Number of subjects: 38